Abstract. The present study aimed to determine whether the expression of lectin-like oxidized LDL receptor 1 (LOX-1) could be induced by oxidized low-density lipoprotein (Ox-LDL) and interleukin 1β (IL-1β) in human mesangial cells (HMCs). Oil Red O staining was used to observe the uptake of Ox-LDL by HMCs stimulated with IL-1β, and reverse transcription-quantitative polymerase chain reaction analysis and western blotting were used to examine the expression of LOX-1 in HMC following Ox-LDL and IL-1β treatment. Uptake of Ox-LDL by HMCs was upregulated upon stimulation with IL-1β. Furthermore, Ox-LDL (10-40 µg/ml) treatment induced LOX-1 mRNA and protein expression in a dose-dependent manner. In addition, when HMCs were treated with IL-1β and Ox-LDL, the expression of LOX-1 was enhanced further. These results indicated that inhibiting LOX-1 expression or inhibiting the Ox-LDL/LOX-1 signaling axis may be a potential novel method for treating renal disease.
Introduction
Various types of renal disease are characterized by an abnormal lipid metabolism, with hyperlipidemia being associated with the progression of renal disease. Previous studies have identified that glomerular sclerosis and atherosclerosis exhibit similar pathological changes and underlying pathophysiological mechanisms (1) (2) (3) . Atherosclerosis is associated with inflammation, while kidney disease often occurs in a microinflammatory state, which suggests that inflammation and lipid metabolism mediates the progression of glomerular sclerosis and kidney disease at the cellular level (1) (2) (3) .
Lectin-like oxidized LDL receptor 1 (LOX-1) is the receptor for oxidized low-density lipoprotein (Ox-LDL). The specific binding of Ox-LDL to LOX-1 causes endothelial dysfunction and serves a role in the formation of atherosclerotic plaques. Therefore, LOX-1 is a key factor in the occurrence and development of atherosclerosis (4) . It has been revealed that the regulation of LOX-1 in human coronary artery endothelial cells by Ox-LDL was positively correlated with the concentration of Ox-LDL (5) . However, the association between Ox-LDL and LOX-1 in mesangial cells remains unclear. LOX-1 expression in endothelial cells can be induced by a variety of proinflammatory cytokines (6) , while the effects of interleukin 1β (IL-1β) on the Ox-LDL/LOX-1 axis is unclear. In the present study, the effect of Ox-LDL on the expression of LOX-1 in human glomerular mesangial cells was examined. In addition, the role of inflammation in this regulation was explored.
Materials and methods
Cell culture and identification. Human glomerular mesangial IP15 cell lines (HMCs; Renal Disease Center, Royal Free Hospital of England; London, UK) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37˚C with 5% CO 2 . The protein expression levels of actin, collagen IV, fibronectin, vimentin, cytokeratin and factor VIII were tested by an indirect immunofluorescence assay using kits for anti-collagen IV antibody (ab6586), anti-β actin antibody (ab8227), anti-fibronectin antibody (ab2413), anti-vimentin antibody (ab137321), anti-wide spectrum cytokeratin antibody (ab9377) and anti-factor VIII antibody (ab203590; all Abcam, Cambridge, UK) according to the previous study (7) .
Lipid staining. The HMCs (1x10 6 cells/ml) were divided into IL-1β treatment (5 ng/ml IL-1β + 0.2% RPMI-1640), where cells were treated for 24 h at 37˚C, and control (0.2% RPMI-1640) groups. The cells were subsequently treated with 40 µg/ml Ox-LDL and cultured for a further 24 h. The cells were then stained with Oil Red O for 15 min at 37˚C and observed under a light microscope.
Flow cytometry. Cells were treated with 2.5, 5 and 10 ng/ml IL-1β for 24 h, respectively. The cells were also treated with IL-1β 5 ng/ml + Ox-LDL and IL-1β 5 ng/ml + LOX-1, respectively. The fluorescence values at 0, 8, 12 and 24 h were detected using the flow cytometry method (8) . Analysis was performed using BD FACSCalibur CELLQuest software version 3.0 (BD Biosciences; Franklin Lakes, NJ, USA).
Ox-LDL cytotoxicity assay. The HMCs were treated with different concentrations of Ox-LDL (0, 40, 80, 100, 120, 150 and 200 µg/ml) for 24 h at 37˚C and cultured in RPMI-1640 medium supplemented with 10% FBS at 37˚C with 5% CO 2 for 24 h. Subsequently, morphological changes in the HMCs were observed under a phase-contrast microscope. The cells were then harvested and digested with trypsin. The cell debris was resuspended with PBS following centrifugation (120 x g for 5 min at room temperature) and the suspension was stained with trypan blue for 5 min at room temperature. The number of HMCs was counted in five randomly selected visual fields and the apoptosis rate was calculated as follows: Apoptosis rate (%) = (number of stained cells/total cell number) x 100. In addition, a lactate dehydrogenase (LDH) release test was performed with an Pierce™ LDH Cytotoxicity Assay Kit (Pierce; Thermo Fischer Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. The optical density was measured at a 490-nm wavelength with a microplate reader.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.
The effects of different concentrations of Ox-LDL and IL-1β on LOX-1 mRNA expression were detected by RT-qPCR. HMCs were divided into the following groups randomly: Control (untreated); Ox-LDL (10, 20, 40 and 60 µg/ml Ox-LDL); 5 ng/ml IL-1β; 40 µg/ml Ox-LDL + 5 ng/ml IL-1β; and 60 µg/ml Ox-LDL + 5 ng/ml IL-1β. Cells were treated with Ox-LDL and IL-1β for 24 h at 37˚C. Total RNA was extracted from the cells using an E.Z.N.A.
® Total RNA kit I (Omega Bio-Tek, Inc., Norcross, GA, USA) according to the manufacturer's protocol. cDNA were synthesized from this RNA using PrimeScript RT master mix (Takara Bio, Inc. Otsu, Japan) following the manufacturer's protocol. Subsequently, qPCR was performed using an ABI 7500 Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with SYBR Premix Ex Taq II (Takara Bio, Inc.) master mix. 10 µM primers and 40 ng cDNA was used. The thermocycling conditions were as follows: Denaturation at 95˚C for 30 sec; 40 amplification cycles at 95˚C for 10 sec; and 60˚C for 30 sec. GAPD was used as the control. The primer sequences were as follows: LOX-1 forward, 5'-ACA GAG GCC ATT CCG AAA TCA-3' and reverse, 5'-GGT AGA GTC TGG AGA TGG ACC ACA-3'; and GAPDH forward, 5'-GCA CCG TCA AGG CTG AGA AC-3' and reverse, 5'-ATG GTG GTG AAG ACG CCA GT-3'. The quantification method used was the 2 -ΔΔCq method as described previously (9) .
Western blotting. LOX-1 protein expression was detected via western blotting. Briefly, 5x10 5 cells/well were seeded into 6-well plates with RPMI-1640 medium containing 10% FBS and cultured for 24 h at 37˚C. The medium was subsequently replaced with RPMI-1640 without serum and the cells were cultured for a further 12 h. The RPMI-1640 with serum was then changed, and the cells were treated with different concentrations of Ox-LDL and IL-1β [Ox-LDL (10, 20, 40 and 60 µg/ml); 5 ng/ml IL-1β; 40 µg/ml Ox-LDL + 5 ng/ml IL-1β; and 60 µg/ml Ox-LDL + 5 ng/ml IL-1β respectively] and cultured for 24 h. The cells were washed twice with cold PBS and lysed with radioimmunoprecipitation assay lysis buffer (Biovision Inc., Palo Alto, CA, USA) for 25 min on ice. The cell lysates were centrifuged at 180 x g for 10 min at 4˚C and protein concentration was measured using the Bradford protein assay (10) . Total protein (50 µg) was separated on a 12% gel using SDS-PAGE. Proteins were transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA), which were blocked with 5% non-fat milk in Tris-buffered saline with Tween-20 [10 mM Tris-HCl (pH 8.0), 150 mM NaCl and 0.1% Tween-20] for 2 h, and then incubated with the primary anti-LOX 1 antibody (dilution 1:1,000; ab60178; Abcam; Cambridge, MA, USA), anti-β-actin antibody (dilution 1:5,000; ab8227; Abcam). at 4˚C overnight. Following this, the membranes were incubated with horseradish peroxidase-conjugated secondary anti-Rabbit IgG (dilution 1:10,000; ab191866; Abcam) at room temperature for 1 h. Protein bands were then detected using an enhanced chemiluminescence detection kit (K820-500; Biovision Inc., Palo Alto, CA, USA). ImageJ software (version 1.37; National Institutes of Health; Bethesda, MD, USA) was used to quantify the results.
Statistical analysis. All data are presented as the mean ± standard deviation. Statistical analysis was performed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). Differences between the experimental groups were analyzed by one-way analysis of the variance and a post hoc Kruskal-Wallis test. P<0.05 was considered to indicate a statistically significant difference.
Results

IL-1β promotes the uptake of Ox-LDL by HMCs.
The results of Oil Red O staining revealed notably more lipid staining around the nucleus of HMCs treated with IL-1β compared with HMCs in the control group (Fig. 1) . This suggests that IL-1β enhances the uptake of Ox-LDL by HMCs.
IL-1β enhances the uptake of Ox-LDL by HMCs in a dose-and time-dependent manner.
The results of immunofluorescence measured using the flow cytometry method after the HMCs were treated with 2.5, 5 or 10 ng/ml IL-1β for 24 h demonstrated that the average fluorescence reached a peak value in the 10 ng/ml IL-1β treatment group (Table I) . Effects of 5 ng/ml IL-1β on uptaking Ox-LDL by HMCs at different times were shown in Table II . Effects of Anti-LOX-1 antibody were shown in Table III . These indicated that IL-1β enhances the uptake of Ox-LDL by HMCs in a dose-and time-dependent manner.
A high Ox-LDL concentration increases HMC apoptosis.
There was no notable difference in the morphology of HMCs treated with 40-120 µg/ml Ox-LDL-treated and the control group (data not shown). However, floating and dead cells were observed in the 150 and 200 µg/ml Ox-LDL-treated groups. Furthermore, the results of trypan blue staining and the LDH release test revealed that apoptosis rate of the HMCs increased after treatment with >120 µg/ml Ox-LDL concentration; treatment with <120 µg/ml Ox-LDL resulted in an apoptosis rate of <5% (Fig. 2) .
Effect of Ox-LDL and IL-1β on the expression of LOX-1.
Ox-LDL treatment (10-40 µg/m;) significantly increased the expression of LOX-1 mRNA in HMCs in a dose-dependent manner (P<0.01 vs. the control group; Fig. 3) . Combining 40 or 60 µg/ml Ox-LDL treatment with 5 ng/ml IL-1β significantly increased the expression of LOX-1 compared with Ox-LDL treatment alone (P<0.01; Fig. 4) . The western blotting results revealed similar increases in LOX-1 protein expression following Ox-LDL or Ox-LDL + IL-1β treatment (Figs. 5 and 6 ).
Discussion
Hyperlipidemia is a common clinical manifestation of renal disease and abnormal lipid metabolism is associated with the progression of renal disease (11) . Hyperlipidemia is an independent risk factor for the occurrence and development of glomerular sclerosis; however, plasma cholesterol levels do not necessarily correlate with the degree of glomerular sclerosis (12, 13) . Glomerular sclerosis and atherosclerosis exhibit similar pathological changes and underlying pathophysiological mechanisms (14) , and inflammation serves a key role in the development of glomerular sclerosis.
The presence of macrophage-derived foam cells is an important feature of early atherosclerosis, while the infiltration of the foam cells derived from mesangial cells in the kidney is a characteristic of glomerular sclerosis (15) . Furthermore, mesangial and vascular smooth muscle cells possess several similar properties, including secretory matrix and cell shrinkage, and can also uptake Ox-LDL. Therefore, it is thought that mesangial cells are associated with lipid-mediated renal damage (16). The present study revealed that HMCs expressed the LOX-1 receptor. Finally, a previous study indicated higher levels of expression of adhesion and inflammatory factors promoted monocyte macrophage accumulation and engulfed the Ox-LDL, which participated in the formation of atherosclerotic plaque (17) . LOX-1 is a key contributing factor to the occurrence and development of atherosclerosis, and to the progression of chronic kidney disease (18) . Additionally, an increase in LOX-1 expression in the renal artery is associated with intimal hyperplasia and renal fibrosis. Furthermore, anti-LOX-1 therapy can reverse the increase of kidney damage caused by diabetes, oxidative stress and leukocyte infiltration, and can improve the renal microvascular bed (19) . Increased expression of LOX-1 in the kidney of type 2 diabetic rats has been demonstrated to aggravate the injury of renal interstitial nephritis, which suggests that it is important in the occurrence and development of diabetic nephropathy (20) .
Previous studies have revealed that Ox-LDL exerts regulation on the LOX-1 receptor in human coronary artery endothelial cells (1,2) , and mesangial cells could uptake Ox-LDL through the LOX-1 receptor signaling pathway, which suggests that the LOX-1 signaling pathway may underlie the pathogenesis of lipid metabolism disorders (21) . The present study revealed that 10-40 µg/ml Ox-LDL could significantly upregulate LOX-1 mRNA and protein expression in HMCs in a dose-dependent manner. Furthermore, LOX-1 expression was increased further by 5 ng/ml IL-1β and Ox-LDL cotreatment. Additionally, IL-1β changed the regulation of Ox-LDL n LOX-1 and promoted the uptake of Ox-LDL by HMCs. Thus, inflammation is a risk factor for the progression of atherosclerosis and nephropathy.
In conclusion, the present study revealed that IL-1β accelerated the uptake of Ox-LDL by HMCs by altering the regulation of Ox-LDL on its receptor LOX-1. These results indicate that inhibiting LOX-1 expression or inhibiting the Ox-LDL/LOX-1 signaling axis are potential novel treatments for renal disease.
